Thus, monitoring albumin levels in MASLD patients is advisable for tracking disease progression, as supported by studies showing significant albumin reduction over a two-year period in untreated MASLD cases [50]. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.